Patient demographics and baseline clinical characteristics
| Characteristic . | No. of patients (n = 29) . |
|---|---|
| Age, y | |
| Median | 63 |
| Range | 38-80 |
| Male sex | 55 |
| International Staging System stage | |
| I | 10 (34) |
| II | 15 (52) |
| III | 4 (14) |
| Albumin, g/dL | |
| Median | 3.62 |
| Range | 2.6-4.5 |
| Paraprotein | |
| IgG | 13 (45) |
| IgA | 9 (31) |
| Free light chain | 15 (52) |
| Other (IgD and IgM) | 0 (0) |
| Eastern Cooperative Oncology Group performance status | |
| 0 | 16 (55) |
| 1 | 11 (38) |
| 2 | 2 (7) |
| No. of previous therapies | |
| Median | 3 |
| Range | 1-6 |
| Type of therapy | |
| Thalidomide only | 4 (14) |
| Lenalidomide only | 13 (45) |
| Lenalidomide + thalidomide | 11 (38) |
| No previous thalidomide or lenalidomide | 1 (3) |
| Bortezomib | 19 (66) |
| Autologous stem cell transplantation | 20 (69) |
| Characteristic . | No. of patients (n = 29) . |
|---|---|
| Age, y | |
| Median | 63 |
| Range | 38-80 |
| Male sex | 55 |
| International Staging System stage | |
| I | 10 (34) |
| II | 15 (52) |
| III | 4 (14) |
| Albumin, g/dL | |
| Median | 3.62 |
| Range | 2.6-4.5 |
| Paraprotein | |
| IgG | 13 (45) |
| IgA | 9 (31) |
| Free light chain | 15 (52) |
| Other (IgD and IgM) | 0 (0) |
| Eastern Cooperative Oncology Group performance status | |
| 0 | 16 (55) |
| 1 | 11 (38) |
| 2 | 2 (7) |
| No. of previous therapies | |
| Median | 3 |
| Range | 1-6 |
| Type of therapy | |
| Thalidomide only | 4 (14) |
| Lenalidomide only | 13 (45) |
| Lenalidomide + thalidomide | 11 (38) |
| No previous thalidomide or lenalidomide | 1 (3) |
| Bortezomib | 19 (66) |
| Autologous stem cell transplantation | 20 (69) |
IgG indicates immunoglobulin G; and IgA, immunoglobulin A.